Weber I R, Neidlein R, von der Saal W, Grams F, Leinert H, Strein K, Engh R A, Kucznierz R
Pharmazeutisch-Chemisches Institut der Universität, Heidelberg, Germany.
Bioorg Med Chem Lett. 1998 Jul 7;8(13):1613-8. doi: 10.1016/s0960-894x(98)00269-8.
Based on the structures of aminopyridine thrombin inhibitors (1), a series of aminoalkyl- and guanidinoalkyl-substituted diarylsulfonamides were prepared. The most potent derivative, N-[3-(4-guanidinobutoxy)-5-methyl-phenyl]-benzenesulfonamide (6c) had Ki = 0.18 microM for thrombin and did not inhibit trypsin, plasmin, or factor Xa. Comparison of the X-ray structures of the thrombin/1b and the thrombin/6c complexes revealed important aspects which govern the binding of such diarylsulfonamides to thrombin.
基于氨基吡啶凝血酶抑制剂(1)的结构,制备了一系列氨基烷基和胍基烷基取代的二芳基磺酰胺。最有效的衍生物N-[3-(4-胍基丁氧基)-5-甲基苯基]-苯磺酰胺(6c)对凝血酶的Ki值为0.18 microM,且不抑制胰蛋白酶、纤溶酶或因子Xa。凝血酶/1b和凝血酶/6c复合物的X射线结构比较揭示了决定此类二芳基磺酰胺与凝血酶结合的重要方面。